Document Detail


Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes.
MedLine Citation:
PMID:  14578244     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: This trial aimed to characterize for the first time the pharmacokinetic profile of insulin detemir, the novel soluble basal insulin analog, in children and adolescents compared with adults. Comparisons were also made with NPH insulin to determine any between-treatment difference in the effect of age on pharmacokinetic profile. RESEARCH DESIGN AND METHODS: This single-center, open-label, randomized, crossover trial included children (aged 6-12 years, n = 13), adolescents (aged 13-17 years, n = 10), and adults (aged 18-65 years, n = 11) of both sexes. Subjects were given single doses of 0.5 units/kg s.c. insulin detemir or 0.5 IU/kg NPH insulin on 2 separate days. Serial blood sampling was performed for 24 h for analysis of serum insulin detemir, human insulin, and glucose concentrations. RESULTS: The mean pharmacokinetic profile of insulin detemir was similar across all three age-groups. This was determined by statistical analyses of the data, which showed no overall age effect or between-group differences when pairwise comparisons were made between children (or adolescents) and adults on the parameters of the area under the curve (AUC), AUC from zero to infinity, AUC from 0 to 24 h [AUC((0-24 h))], and the maximum concentration measured during the 24 h after closing. No overall age effect for AUC((0-24 h)) and C(max) was detected for NPH insulin, but data were only analyzable from seven adults and pairwise comparisons did indicate that children and adults had different pharmacokinetic profiles. Less total variability in the pharmacokinetics of insulin detemir than NPH insulin was indicated by lower coefficients of variation in AUC, C(max), and time to maximum concentration in all three age-groups. CONCLUSIONS: The data suggest that insulin detemir can be used in children and adolescents with type 1 diabetes using titration guidelines similar to those used in adults. Moreover, insulin detemir may offer the advantage of greater predictability of response in comparison to NPH insulin due to lower total variability and a lesser degree of kinetic disparity across age-groups.
Authors:
Thomas Danne; Kerstin Lüpke; Kerstin Walte; Wolfgang Von Schuetz; Mari-Anne Gall
Related Documents :
1675054 - Regulation of glucose metabolism in man.
1647334 - Basal and insulin stimulated substrate metabolism in tumour induced hypoglycaemia; evid...
9727844 - Experience of severe hypoglycaemia may influence both patient's and physician's subsequ...
8354984 - Non-paroxysmal arterioventricular junctional tachycardia during postprandial hypoglycae...
9797494 - Coronary heart disease mortality amongst non-insulin-dependent diabetic subjects in ice...
12688434 - The asheville project: factors associated with outcomes of a community pharmacy diabete...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Diabetes care     Volume:  26     ISSN:  0149-5992     ISO Abbreviation:  Diabetes Care     Publication Date:  2003 Nov 
Date Detail:
Created Date:  2003-10-27     Completed Date:  2004-06-24     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  7805975     Medline TA:  Diabetes Care     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3087-92     Citation Subset:  IM    
Affiliation:
Kinderkrankenhaus auf der Bult, Hannover, Germany. danne@hka.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Age Factors
Aged
Carrier Proteins / adverse effects,  blood,  pharmacokinetics*
Child
Cross-Over Studies
Diabetes Mellitus, Type 1 / drug therapy*
Female
Humans
Hypoglycemic Agents / adverse effects,  blood,  pharmacokinetics*
Insulin / adverse effects,  analogs & derivatives*,  blood,  pharmacokinetics*
Insulin, NPH / adverse effects,  blood,  pharmacokinetics
Male
Middle Aged
Chemical
Reg. No./Substance:
0/Carrier Proteins; 0/Hypoglycemic Agents; 0/insulin detemir; 11061-68-0/Insulin; 53027-39-7/Insulin, NPH

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of t...
Next Document:  Archimedes: a trial-validated model of diabetes.